Trial Profile
Ascending single dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of SKI-606 administered orally to healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Apr 2012
Price :
$35
*
At a glance
- Drugs Bosutinib (Primary)
- Indications Myeloid leukaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Wyeth
- 15 Nov 2009 Results were presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
- 13 Dec 2006 New trial record.